ARQIS advises Quadriga Capital on investment in United Therapy

10. March 2022

ARQIS has advised Quadriga Capital Fonds (“Quadriga Capital”) as shareholders of the emerging physiotherapy group UNITED THERAPY.

With the merger of UNITED THERAPY, which arises from NOVOTERGUM GmbH and Deutsche Arzt AG, a new provider in the German physiotherapy market is being formed with the support of Quadriga Capital. It will combine analog physiotherapy with digital telemedicine services. The goal of the physiotherapy group is to be an innovative ecosystem and network for holistic care solutions.

Quadriga Capital, Luxempart S.A., Deutsche Arzt AG and NOVO-T AG signed the merger agreement at the end of February. The transaction is expected to close in the first quarter of 2022. Jochen Roeser, spokesman for the management board of NOVOTERGUM GmbH, will become the future CEO of UNITED THERAPY, which can already count on more than 600 employees at the start and is planning further growth.

NOVO-T AG brings its subsidiary NOVOTERGUM GmbH, one of the leading physiotherapy chains with over 50 locations in Germany, into the merger. Deutsche Arzt AG contributes its innovative digital appbased solutions for therapy management and prevention, as well as its health insurance direct contracts and national orthopedic care network. As part of the transaction, Deutsche Arzt AG is transferring its business operations to Deutsche Arzt Management GmbH, a subsidiary of UNITED THERAPY. The Luxembourg-based, listed investment company Luxempart S.A. is leaving the group of shareholders after three years of successful support.

Quadriga Capital is an experienced partner in the transformation of healthcare companies. The healthcare, tech-enabled services and smart industries sectors are the focus of Quadriga Capital’s longterm and sustainable investments.

The ARQIS team led by Jörn-Christian Schulze has many years of successful experience supporting financial investors, particularly in the healthcare and nursing sector. The team was most recently active for Quadriga Capital in the acquisition and expansion of the care platform wecare.


Advisors to Quadriga Capital

ARQIS: Dr. Jörn-Christian Schulze (Lead), Johannes Landry, Dr. Ulrich Lienhard, Marcus Nothhelfer, Dr. Hendrik von Mellenthin; Counsel: Sina Janke, Jens Knipping, Saskia Kirschbaum, Anja Markworth; Associates: Kamil Flak (Lead Due Diligence), Severin Steffens, Dr. Nima Hanifi-Atashgah, Nora Meyer-Stratmann, Martin Weingärtner, Dr. Martina Berenbrinker, Tim Bresemann, Christos Choudeloudis, Laura Rizzi, Daniel Schlemann, Jasmin Stuckenbrock, Rolf Tichy, Nathalie Wintermeier; Legal Specialists: Carina Grahs, Gloria Bittner-Schützendorf, Maria Fischer, Hannah Potter, Julia Regenauer, Qing Xia


If you have any questions, please write to us.